Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly

16 Sept 2017

Abstract excerpt

Significant progress in the manufacturing of biopharmaceuticals has been made by increasing the overall titers in the USP (upstream processing) titers without raising the cost of the USP. In addition, the development of platform processes led to a higher process robustness. Despite or even due to those achievements, novel challenges are in sight. The higher upstream titers created more complex impurity profiles,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31548528
DOI: 10.3390/antib6030013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the UglyPMID 31548528Read ↗

Host cell proteins in biologics development: Identification, quantitation and risk assessmentSemantic proximity Read ↗

Identification and classification of host cell proteins during biopharmaceutical process developmentSemantic proximity Read ↗

Characterisation of the E. coli HMS174 and BLR host cell proteome to guide purification process developmentSemantic proximity Read ↗

Profiling of host cell proteins by two‐dimensional difference gel electrophoresis (2D‐DIGE): Implications for downstream process developmentSemantic proximity Read ↗

Expression of difficult‐to‐remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessingSemantic proximity Read ↗

Applications of proteomic methods for CHO host cell protein characterization in biopharmaceutical manufacturingSemantic proximity Read ↗

A novel approach to evaluate ELISA antibody coverage of host cell proteins—combining ELISA‐based immunocapture and mass spectrometrySemantic proximity Read ↗

A comparison of different intensified upstream processes highlighting the advantage of WuXiUP in improved product quality and simplified downstream processSemantic proximity Read ↗

Development of therapeutic proteins: advances and challengesSemantic proximity Read ↗

Holistic Analytical Characterization and Risk Assessment of Residual Host Cell Protein Impurities in an Active Pharmaceutical Ingredient (API) Synthesized by BiocatalystsSemantic proximity Read ↗

Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of “Problematic” Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2)Semantic proximity Read ↗

Recent advances in (therapeutic protein) drug developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.